These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38029742)

  • 21. Rational prediction of immunogenicity clustering through cross-reactivity analysis of thirteen SARS-CoV-2 variants.
    Liang Z; Tong J; Sun Z; Liu S; Wu J; Wu X; Li T; Yu Y; Zhang L; Zhao C; Lu Q; Nie J; Huang W; Wang Y
    J Med Virol; 2024 Jan; 96(1):e29314. PubMed ID: 38163276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86.
    Lasrado N; Collier AY; Hachmann NP; Miller J; Rowe M; Schonberg ED; Rodrigues SL; LaPiana A; Patio RC; Anand T; Fisher J; Mazurek CR; Guan R; Wagh K; Theiler J; Korber BT; Barouch DH
    Vaccine; 2023 Nov; 41(47):6904-6909. PubMed ID: 37872011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.
    Akerman A; Milogiannakis V; Jean T; Esneau C; Silva MR; Ison T; Fichter C; Lopez JA; Chandra D; Naing Z; Caguicla J; Li D; Walker G; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Foster CSP; Sato K; Lee S; Song Y; Mao L; Sigmund A; Phu A; Vande More AM; Hunt S; Douglas M; Caterson I; Britton W; Sandgren K; Bull R; Lloyd A; Triccas J; Tangye S; Bartlett NW; Darley D; Matthews G; Stark DJ; Petoumenos K; Rawlinson WD; Murrell B; Brilot F; Cunningham AL; Kelleher AD; Aggarwal A; Turville SG
    EBioMedicine; 2023 Apr; 90():104545. PubMed ID: 37002990
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
    Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
    Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1.
    Wang Q; Guo Y; Bowen A; Mellis IA; Valdez R; Gherasim C; Gordon A; Liu L; Ho DD
    Cell Host Microbe; 2024 Mar; 32(3):315-321.e3. PubMed ID: 38377995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
    Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L
    Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3.
    Faraone JN; Qu P; Goodarzi N; Zheng YM; Carlin C; Saif LJ; Oltz EM; Xu K; Jones D; Gumina RJ; Liu SL
    Emerg Microbes Infect; 2023 Dec; 12(2):2270069. PubMed ID: 37819267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
    Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M
    J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 Neutralization Capacity in Hemodialysis Patients with and without a Fifth Vaccination with the Updated Comirnaty Original/Omicron BA.4-5 Vaccine.
    Liao BH; Platen L; Grommes M; Cheng CC; Holzmann-Littig C; Christa C; Haller B; Kappler V; Bester R; Werz ML; Platen E; Eggerer P; Tréguer L; Küchle C; Schmaderer C; Heemann U; Renders L; Protzer U; Braunisch MC
    Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 Variants Omicron BA.4/5 and XBB.1.5 Significantly Escape T Cell Recognition in Solid-organ Transplant Recipients Vaccinated Against the Ancestral Strain.
    Halvorson T; Ivison S; Huang Q; Ladua G; Yotis DM; Mannar D; Subramaniam S; Ferreira VH; Kumar D; Belga S; Levings MK;
    Transplantation; 2024 Apr; 108(4):e49-e62. PubMed ID: 38012843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Establishment of the First National Standard for Neutralizing Antibodies against SARS-CoV-2 XBB Variants.
    Zhang X; Guan L; Li N; Wang Y; Li L; Liu M; He Q; Lu J; Zeng H; Yu S; Guo X; Gong J; Li J; Gao F; Wu X; Chen S; Wang Q; Wang Z; Huang W; Mao Q; Liang Z; Xu M
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants.
    Qu P; Xu K; Faraone JN; Goodarzi N; Zheng YM; Carlin C; Bednash JS; Horowitz JC; Mallampalli RK; Saif LJ; Oltz EM; Jones D; Gumina RJ; Liu SL
    Cell; 2024 Feb; 187(3):585-595.e6. PubMed ID: 38194968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal Analysis of Humoral and Cellular Immune Response up to 6 Months after SARS-CoV-2 BA.5/BF.7/XBB Breakthrough Infection and BA.5/BF.7-XBB Reinfection.
    Wang X; Zhang M; Wei K; Li C; Yang J; Jiang S; Zhao C; Zhao X; Qiao R; Cui Y; Chen Y; Li J; Cai G; Liu C; Yu J; Zhang W; Xie F; Wang P; Zhang Y
    Vaccines (Basel); 2024 Apr; 12(5):. PubMed ID: 38793715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages.
    Ai J; Wang X; He X; Zhao X; Zhang Y; Jiang Y; Li M; Cui Y; Chen Y; Qiao R; Li L; Yang L; Li Y; Hu Z; Zhang W; Wang P
    Cell Host Microbe; 2022 Aug; 30(8):1077-1083.e4. PubMed ID: 35594867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection.
    Yang J; Hong W; Lei H; He C; Lei W; Zhou Y; Zhao T; Alu A; Ma X; Li J; Yang L; Wang Z; Wang W; Lu G; Shen G; Lu S; Wu G; Shi H; Wei X
    Signal Transduct Target Ther; 2023 Jun; 8(1):252. PubMed ID: 37336889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
    Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD
    Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Neutralizing Activity against Omicron Subvariants in BA.5 Breakthrough Infection and Three-Dose Vaccination Using a Novel Chemiluminescence-Based, Virus-Mediated Cytopathic Assay.
    Toyoda M; Tan TS; Motozono C; Barabona G; Yonekawa A; Shimono N; Minami R; Nagasaki Y; Miyashita Y; Oshiumi H; Nakamura K; Matsushita S; Kuwata T; Ueno T
    Microbiol Spectr; 2023 Aug; 11(4):e0066023. PubMed ID: 37310218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1.
    Sullivan DJ; Franchini M; Senefeld JW; Joyner MJ; Casadevall A; Focosi D
    J Gen Virol; 2023 May; 104(5):. PubMed ID: 37167085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A long-term cohort study: the immune evasion and decreasing neutralization dominated the SARS-CoV-2 breakthrough infection.
    Liu Q; Jin M; Mei F; Fan H; Gu M; Zhang Y; Qian S; Tan X; Ji L; Zhang Z; Chen G; Yan H; Chen Y; Lan K; Geng Q; Cai K; Zhou L
    Front Cell Infect Microbiol; 2024; 14():1381877. PubMed ID: 38572316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.